TY - JOUR
T1 - Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-kB signaling pathway
AU - Dou, Wei
AU - Zhang, Jingjing
AU - Zhang, Eryun
AU - Sun, Aning
AU - Ding, Lili
AU - Chou, Guixin
AU - Wang, Zhengtao
AU - Mani, Sridhar
PY - 2013/6
Y1 - 2013/6
N2 - Targeted activation of pregnane X receptor (PXR) in recent years has become a therapeutic strategy for inflammatory bowel disease. Chrysin is a naturally occurring flavonoid with antiinflammation activity. The current study investigated the role of chrysin as a putative mouse PXR agonist in preventing experimental colitis. Pre-administration of chrysin ameliorated inflammatory symptoms in mouse models of colitis (dextran sodium sulfate-and 2,4,6-trinitrobenzene sulfonic acid-induced) and resulted in down-regulation of nuclear transcription factor kB (NF-kB) target genes (inducible NO synthase, intercellular adhesion molecule-1, monocyte chemotactic protein-1, cyclooxygenase 2, tumor necrosis factor-a, and interleukin 6) in the colon mucosa. Chrysin inhibited the phosphorylation/degradation of inhibitor kBa (IkBa), which correlated with the decrease in the activity of myeloperoxidase and the levels of tumor necrosis factor-a and interleukin 6 in the colon. Consistent with the in vivo results, chrysin blocked lipopolysaccharide-stimulated nuclear translocation of NF-kB p65 in mouse macrophage RAW264.7. Furthermore, chrysin dose-dependently activated human/mouse PXR in reporter gene assays and up-regulated xenobiotic detoxification genes in the colon mucosa, but not in the liver. Silencing of PXR by RNA interference demonstrated necessity of PXR in mediating chrysin's ability to induce xenobiotic detoxification genes and NF-kB inactivation. The repression of NF-kB transcription activity by chrysin was confirmed by in vitro PXR transduction. These findings suggest that the effect of chrysin in preventing chemically induced colitis is mediated in large part by a PXR/NF-kB pathway. The data also suggest that chrysin or chrysin-like flavonoids could be further developed as intestine-specific PXR activators.
AB - Targeted activation of pregnane X receptor (PXR) in recent years has become a therapeutic strategy for inflammatory bowel disease. Chrysin is a naturally occurring flavonoid with antiinflammation activity. The current study investigated the role of chrysin as a putative mouse PXR agonist in preventing experimental colitis. Pre-administration of chrysin ameliorated inflammatory symptoms in mouse models of colitis (dextran sodium sulfate-and 2,4,6-trinitrobenzene sulfonic acid-induced) and resulted in down-regulation of nuclear transcription factor kB (NF-kB) target genes (inducible NO synthase, intercellular adhesion molecule-1, monocyte chemotactic protein-1, cyclooxygenase 2, tumor necrosis factor-a, and interleukin 6) in the colon mucosa. Chrysin inhibited the phosphorylation/degradation of inhibitor kBa (IkBa), which correlated with the decrease in the activity of myeloperoxidase and the levels of tumor necrosis factor-a and interleukin 6 in the colon. Consistent with the in vivo results, chrysin blocked lipopolysaccharide-stimulated nuclear translocation of NF-kB p65 in mouse macrophage RAW264.7. Furthermore, chrysin dose-dependently activated human/mouse PXR in reporter gene assays and up-regulated xenobiotic detoxification genes in the colon mucosa, but not in the liver. Silencing of PXR by RNA interference demonstrated necessity of PXR in mediating chrysin's ability to induce xenobiotic detoxification genes and NF-kB inactivation. The repression of NF-kB transcription activity by chrysin was confirmed by in vitro PXR transduction. These findings suggest that the effect of chrysin in preventing chemically induced colitis is mediated in large part by a PXR/NF-kB pathway. The data also suggest that chrysin or chrysin-like flavonoids could be further developed as intestine-specific PXR activators.
UR - http://www.scopus.com/inward/record.url?scp=84878028859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878028859&partnerID=8YFLogxK
U2 - 10.1124/jpet.112.201863
DO - 10.1124/jpet.112.201863
M3 - Article
C2 - 23536316
AN - SCOPUS:84878028859
SN - 0022-3565
VL - 345
SP - 473
EP - 482
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 3
ER -